Case Report of a Pregnancy During Ipilimumab Therapy

The most common malignancy during pregnancy is melanoma, and approximately one third of all women diagnosed with melanoma are of childbearing age.1,2 Thus, the effects of the drugs used in the treatment of melanoma on reproduction and development is of high interest. Ipilimumab, an anti–cytotoxic T-cell lymphocyte-4 (CTLA-4) antibody, was approved for the therapy of metastatic melanoma in 2011. We describe what we believe is the first report with follow-up of the successful outcome of a pregnancy in a patient who received ipilimumab therapy for metastatic melanoma.